Half-year report · Q2
3034.TEDINET S100URNY
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥79.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥173m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥801m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥142m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥237m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for bonuses | Prior1YearInstant | 2436000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 2484000000 | JPY |
| Refund liabilities cl | Prior1YearInstant | － | JPY |
| Refund liabilities cl | CurrentQuarterInstant | 6694000000 | JPY |
| Other cl | Prior1YearInstant | 3935000000 | JPY |
| Other cl | CurrentQuarterInstant | 8905000000 | JPY |
| Current liabilities | Prior1YearInstant | 38823000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 55496000000 | JPY |
| Long term loans payable | Prior1YearInstant | 23477000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 19569000000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 302000000 | JPY |
| Deferred tax liabilities | CurrentQuarterInstant | 302000000 | JPY |
| Provision for directors retirement benefits | Prior1YearInstant | 31000000 | JPY |
| Provision for directors retirement benefits | CurrentQuarterInstant | 148000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 859000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 876000000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 1093000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 1174000000 | JPY |
| Other ncl | Prior1YearInstant | 353000000 | JPY |
| Other ncl | CurrentQuarterInstant | 1758000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 26118000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 23832000000 | JPY |
| Liabilities | Prior1YearInstant | 64941000000 | JPY |
| Liabilities | CurrentQuarterInstant | 79328000000 | JPY |
| Capital stock | Prior1YearInstant | 5786000000 | JPY |
| Capital stock | CurrentQuarterInstant | 5786000000 | JPY |
| Capital surplus | Prior1YearInstant | 11276000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 11301000000 | JPY |
| Retained earnings | Prior1YearInstant | 38030000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 38676000000 | JPY |
| Treasury stock | Prior1YearInstant | -2303000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -2133000000 | JPY |
| Shareholders equity | Prior1YearInstant | 52790000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 53631000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | -0 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 10000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | － | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 250000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | -0 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 260000000 | JPY |
| Non controlling interests | Prior1YearInstant | 48000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 4065000000 | JPY |
| Net assets | Prior1YearInstant | 52837000000 | JPY |
| Net assets | CurrentQuarterInstant | 57957000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 117779000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 137286000000 | JPY |
| Net sales | Prior1YTDDuration | 88540000000 | JPY |
| Net sales | CurrentYTDDuration | 124771000000 | JPY |
| Cost of sales | Prior1YTDDuration | 77508000000 | JPY |
| Cost of sales | CurrentYTDDuration | 105722000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |